Next report date
Report period
Q1 2024
EPS estimate
0.62CHF
Revenue estimate
180.19 MCHF
1.804CHF
237.08 MCHF
698.18 MCHF
125.65 M
About Halozyme Therapeutics, Inc.
Sector
Industry
CEO
Helen I. Torley
Website
Headquarters
San Diego
Employees (FY)
373
Founded
1998
FIGI
BBG00LVDJMV7
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
HALO Daily safe bet pharma swingVRTX I already own, looking to add some more pharma in due time.
HALO has good upside, I calculate +25 pct from 41.16 buy point to dashed line 51.63. 21/50/100 EMA crossover.
17.5 pct ROIC, 5.1 pct free cash flow yield (so so), accelerating revenue growth, buybacks, ROE 105%, Operating margin, 42
Halozyme Therapeutics (HALO) - Frequency Formula Strategy - LongStrategy Overview: The Frequency Formula
Our trading strategy, "The Frequency Formula," is built on cutting-edge Fourier Wave Transform theory. The strategy utilizes four unique indicators: the Frequency Formula Chop Indicator (FF-CI), Frequency Formula Trend Indicator (FF-TI), the Frequency Formu
🟨 2023 WATCHLIST: $HALO2023 WATCHLIST
A series of stocks that i will be monitoring at the beginning of 2023
Here is a new issue from the Biomed Industry.
Relative Strength (IBD): 97
IPO: 2007
Sales acceleration:
Jun-22: 12%
Sep-22: 80%
Funds acceleration:
Jun-22: 708
Sep-22: 743
HALO: Bullish Pennant, not confirmed (+38%)Halo is showing yet again some positive pattern in price action.
Currently building into a bullish pennant (not confirmed) after last week's ascending triangle.
If the price action breaks the top of the flag with volume, we may be in for a 36-37% profit.
Target #1 on confirmed flag = 79.83$
Target
$HALO - Green Line Break and confluence of positive indicatorsMultiple bullish indication on $HALO - see chart annotation for details.
GLB - Green Line Break - breakout of previous ATH and consolidation for >3months.
HALO 2Mtest
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinan
HALO: Ascending Triangle WEEKLY (+70%)Hello all,
Haven't posted anything bullish in quite a while but I believe this one is worth a look.
Thank you to @TORNADOF5 for suggesting it.
HALO seem to have been untouched by the pandemic downtrend, as have many pharmaceutical companies.
So looking at the weekly chart, the price action has bu
W PatternPrice has turned just above the 1.113 for now if that 4th leg of the W is finished.
Short interest is around 8%.
No recommendation.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where RV7 is featured.
Frequently Asked Questions
The current price of RV7 is 34.825 CHF — it has decreased by 26.67% in the past 24 hours. Watch HALOZYME THERAPEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange HALOZYME THERAPEUT stocks are traded under the ticker RV7.
HALOZYME THERAPEUT is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
RV7 stock is 36.36% volatile and has beta coefficient of 1.09. Track HALOZYME THERAPEUT stock price on the chart and check out the list of the most volatile stocks — is HALOZYME THERAPEUT there?
RV7 earnings for the last quarter are 0.69 CHF per share, whereas the estimation was 0.65 CHF resulting in a 6.21% surprise. The estimated earnings for the next quarter are 0.67 CHF per share. See more details about HALOZYME THERAPEUT earnings.
HALOZYME THERAPEUT revenue for the last quarter amounts to 197.78 M CHF despite the estimated figure of 197.82 M CHF. In the next quarter revenue is expected to reach 194.49 M CHF.
Yes, you can track HALOZYME THERAPEUT financials in yearly and quarterly reports right on TradingView.
RV7 stock hasn't changed in a week, the last month showed zero change in price, over the last year HALOZYME THERAPEUT has showed a 26.67% decrease.
RV7 net income for the last quarter is 71.89 M CHF, while the quarter before that showed 74.92 M CHF of net income which accounts for −4.04% change. Track more HALOZYME THERAPEUT financial stats to get the full picture.
Today HALOZYME THERAPEUT has the market capitalization of 4.58 B, it has decreased by 7.76% over the last week.
No, RV7 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RV7 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HALOZYME THERAPEUT stock right from TradingView charts — choose your broker and connect to your account.
As of May 3, 2024, the company has 373.00 employees. See our rating of the largest employees — is HALOZYME THERAPEUT on this list?
We've gathered analysts' opinions on HALOZYME THERAPEUT future price: according to them, RV7 price has a max estimate of 65.58 CHF and a min estimate of 35.52 CHF. Watch RV7 chart and read a more detailed HALOZYME THERAPEUT stock forecast: see what analysts think of HALOZYME THERAPEUT and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HALOZYME THERAPEUT EBITDA is 355.63 M CHF, and current EBITDA margin is 50.94%. See more stats in HALOZYME THERAPEUT financial statements.